Patient outcomes status after combination therapy with duv/romi in multicenter R/R cohort
| Clinical outcomes . | All (N = 38) . |
|---|---|
| Outcomes in responders following duv/romi, n (%) | 17/38 (45) |
| On active duv/romi therapy | 3/17 (18) |
| PR on duv/romi, PD despite switch to pralatrexate | 1/17 (6) |
| Discontinued duv/romi due to patient preference | 1/17 (6) |
| Bridged to allo-HSCT | 11/17 (65) |
| CR at day 100 | 10/11 (91) |
| CR at day +290 | 3/10 (30) |
| PD after day 200 | 2/10 (20)∗ |
| Not yet evaluable (day <100) | 1/11 (9) |
| Death due to duv/romi AE | 1/17 (6) |
| Outcomes in PD, n (%) | 21/38 (55) |
| Salvage therapy after duv/romi | 14/21 (67) |
| Death due to lymphoma | 6/21 (29) |
| Hospice care, no known death at data cutoff | 1/21 (5) |
| Therapy received directly after duv/romi progression and response, n (%) | 14/21 (66) |
| CFT74455 (IKZF1/3 degrader) | 3/21 (14) |
| CR + bridge to allo-HSCT | 1 (5) |
| PD | 2 (10) |
| Azacitidine, not evaluable, transition to hospice | 1/21 (5) |
| Azacitidine + lenalidomide, CR† | 1/21 (5) |
| Alemtuzumab, CR + bridge to allo-HSCT | 1/21 (5) |
| Brentuximab vedotin + gemcitabine, PD | 1/21 (5) |
| Dexamethasone + methotrexate,‡ PD | 1/21 (5) |
| GVD, PD | 1/21 (5) |
| GCD, not evaluable, transition to hospice | 1/21 (5) |
| GemDOx, PD | 1/21 (5) |
| Gemcitabine, PD | 1/21 (5) |
| Mogamulizumab, PD | 1/21 (5) |
| Duv + ruxolitinib, not evaluable, transition to hospice | 1/21 (5) |
| Clinical outcomes . | All (N = 38) . |
|---|---|
| Outcomes in responders following duv/romi, n (%) | 17/38 (45) |
| On active duv/romi therapy | 3/17 (18) |
| PR on duv/romi, PD despite switch to pralatrexate | 1/17 (6) |
| Discontinued duv/romi due to patient preference | 1/17 (6) |
| Bridged to allo-HSCT | 11/17 (65) |
| CR at day 100 | 10/11 (91) |
| CR at day +290 | 3/10 (30) |
| PD after day 200 | 2/10 (20)∗ |
| Not yet evaluable (day <100) | 1/11 (9) |
| Death due to duv/romi AE | 1/17 (6) |
| Outcomes in PD, n (%) | 21/38 (55) |
| Salvage therapy after duv/romi | 14/21 (67) |
| Death due to lymphoma | 6/21 (29) |
| Hospice care, no known death at data cutoff | 1/21 (5) |
| Therapy received directly after duv/romi progression and response, n (%) | 14/21 (66) |
| CFT74455 (IKZF1/3 degrader) | 3/21 (14) |
| CR + bridge to allo-HSCT | 1 (5) |
| PD | 2 (10) |
| Azacitidine, not evaluable, transition to hospice | 1/21 (5) |
| Azacitidine + lenalidomide, CR† | 1/21 (5) |
| Alemtuzumab, CR + bridge to allo-HSCT | 1/21 (5) |
| Brentuximab vedotin + gemcitabine, PD | 1/21 (5) |
| Dexamethasone + methotrexate,‡ PD | 1/21 (5) |
| GVD, PD | 1/21 (5) |
| GCD, not evaluable, transition to hospice | 1/21 (5) |
| GemDOx, PD | 1/21 (5) |
| Gemcitabine, PD | 1/21 (5) |
| Mogamulizumab, PD | 1/21 (5) |
| Duv + ruxolitinib, not evaluable, transition to hospice | 1/21 (5) |
GCD, gemcitabine, carboplatin, and dexamethasone; GVD, gemcitabine, vinorelbine, and doxorubicin with pralatrexate in cycle 1 only; GemDOx, gemcitabine, oxaliplatin, and dexamethasone.
One patient had relapsed disease after bridging to allo-HSCT, for which they were retreated with combination duv/romi. They achieved a response to retreatment, bridged to a second allo-HSCT, and remain in remission.
Patient developed Epstein–Barr virus viremia–related extranodal natural killer/T-cell lymphoma from severe immunocompromise during cycle 2 and was thus not bridged to allo-HSCT.
Patient developed central nervous system involvement and hence methotrexate was added.